Events

How Digital Tools are Transforming the Way We Do Science

When:
Mar 13, 2012 12:00 p.m. to 1:30 p.m.
Where:

MaRS Centre, CR-3
101 College Street
Toronto, ON

Modern consumers use a plethora of digital resources to make decisions. From booking hotels, to choosing restaurants or the next hot gadget, we have access to the experience of thousands of other users to help us make a sound choice. But when we put on our labcoats, too often we lower our standards and expectations when it comes to product sourcing for science, relying on guesswork and limited past experience.

Why do we spend more time searching for the best $100/night hotel than we do for a $400 antibody or $1000 kit – especially given the huge implications they can have for our professional success? Why do we not demand the same degree of third party evaluation for our scientific products, relying instead on the word of manufacturers?

All that’s about to change. The world is shifting, as more and more tools are cropping up that change the way we do science. More effective product sourcing, easy-to-use lab management tools, better ways to transfer and share data, new ways to keep up with publications and news – the rise of digital tools in science is making the process at the bench more efficient and effective. And many of them are free.

Alex will be sharing her experience building 1DegreeBio, some of the hottest new digital tools for science, and how the research community needs to change the way it supports digital tools within its institutions and labs.

Part of the MaRS Future of Medicine™ Series



 

In This Series

Past Events

MaRS Programming
May 14, 2012
MaRS Future of Medicine™
Assessing Breast Cancer Risk
>
MaRS Programming
Apr 11, 2012
MaRS Future of Medicine™
Why did they invest in that?
>
MaRS Programming
Mar 13, 2012
MaRS Future of Medicine™
How Digital Tools are Transforming the Way We Do Science
>
MaRS Programming
Feb 14, 2012
MaRS Future of Medicine™
Personalized Cancer Treatment
>
MaRS Programming
Jan 10, 2012
MaRS Future of Medicine™
The Renaissance of Gene Therapy
>
MaRS Programming
Nov 24, 2011
MaRS Future of Medicine™
Building a Self-Sustaining Medical Research Engine: The Ontario Cancer Biomarker Network
>
MaRS Programming
Nov 17, 2011
MaRS Future of Medicine™
MaRS Future of Medicine™ Conference 2011
>
MaRS Programming
Oct 27, 2011
MaRS Future of Medicine™
Financing Early Stage Companies in Challenging Times
>
MaRS Programming
Sep 29, 2011
MaRS Future of Medicine™
Truths and Myths about Life Science Venture Capital
>
MaRS Programming
Aug 25, 2011
MaRS Future of Medicine™
Teaching old drugs new tricks – developing new therapies for patients with leukemia
>
MaRS Programming
Jul 28, 2011
MaRS Future of Medicine™
Adventures in Private Biotech Financing – A company perspective
>
MaRS Programming
May 26, 2011
MaRS Future of Medicine™
Lessons from the Device Battlefield
>
MaRS Programming
Apr 29, 2011
MaRS Future of Medicine™
What does Pharma want, anyway? Presenting your opportunity effectively
>
MaRS Programming
Mar 31, 2011
MaRS Future of Medicine™
Private capital for life science companies
>
MaRS Programming
Feb 24, 2011
MaRS Future of Medicine™
CCRM: Open source innovation in regenerative medicine
>
MaRS Programming
Dec 02, 2010
MaRS Future of Medicine™
MaRS Future of Medicine Conference 2010
>
MaRS Programming
Dec 01, 2010
MaRS Future of Medicine™
What you need to know about regulatory affairs
>
MaRS Programming
Nov 01, 2010
MaRS Future of Medicine™
The View from Bay Street
>
MaRS Programming
Sep 10, 2010
MaRS Future of Medicine™
Anticipating a world in which pharmaceutical companies outsource all R&D
>
MaRS Programming
Aug 24, 2010
MaRS Future of Medicine™
QANTD (Quick And Not Too Dirty) Forecasting
>
 
Jul 26, 2010
MaRS Future of Medicine™
Lessons Learned as an Entrepreneur
>
MaRS Programming
Jun 04, 2010
MaRS Future of Medicine™
Cytochrome-targeted therapeutics for chronic kidney disease
>
MaRS Programming
May 27, 2010
MaRS Future of Medicine™
International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters
>
MaRS Programming
Apr 05, 2010
MaRS Future of Medicine™
A new approach to the treatment of liver cancer
>
MaRS Programming
Mar 12, 2010
MaRS Future of Medicine™
Predicting disease outcome via gene expression analysis
>
MaRS Programming
Feb 12, 2010
MaRS Future of Medicine™
Leading 21st century health care, non-invasive treatment for prostate cancer
>
MaRS Programming
Dec 02, 2009
MaRS Future of Medicine™
Health Economic and Reimbursement Implications for Emerging Pharmaceutical/ Biotechnology Companies: Strategies and perspectives
>
MaRS Programming
Nov 13, 2009
MaRS Future of Medicine™
Targeting Alzheimer’s Disease Progression – from a lead molecule to clinical development
>
MaRS Programming
Nov 12, 2009
MaRS Future of Medicine™
MaRS Future of Medicine Conference
>
MaRS Programming
Oct 09, 2009
MaRS Future of Medicine™
Human pluripotent stem cells for drug discovery
>
 
Sep 17, 2009
MaRS Future of Medicine™
Revitalizing drug discovery with in vivo screening
>
MaRS Programming
Sep 11, 2009
MaRS Future of Medicine™
CHEMSAS® system for drug lead optimization
>
MaRS Programming
Jul 06, 2009
MaRS Future of Medicine™
Disease specific epitopes immunotherapies
>
MaRS Programming
Jun 01, 2009
MaRS Future of Medicine™
Controlled trans-lymphatic chemotherapy for the treatment of lymphatic metastasis in lung cancer
>
MaRS Programming
May 15, 2009
MaRS Future of Medicine™
Overcoming process development and biologics manufacturing challenges
>
MaRS Programming
Dec 16, 2008
MaRS Future of Medicine™
Is there a place for in-vivo pharmacology in modern drug discovery?
>
MaRS Programming
Mar 27, 2008
MaRS Future of Medicine™
Structure-Guided Discovery Without Structures: Computer-aided design of GPCR ligands
>
MaRS Programming
Feb 27, 2008
MaRS Future of Medicine™
Formulation: Giving new life to naturally occurring un-patentable compounds
>
MaRS Programming
Jan 25, 2008
MaRS Future of Medicine™
Novel therapeutic targets for preventing bone loss in osteolytic disease
>
MaRS Programming
Dec 18, 2007
MaRS Future of Medicine™
Outsourcing Preclinical Development
>
MaRS Programming
Oct 23, 2006
MaRS Future of Medicine™
Chance and Necessity in Drug Discovery: The case history of calcimimetic drugs
>
MaRS Programming
Aug 31, 2006
MaRS Future of Medicine™
Structure-based Lead Generation and Optimization
>
MaRS Programming
Jun 29, 2006
>
MaRS Programming
Apr 27, 2006
MaRS Future of Medicine™
BioMarkers in Clinical Trials
>
 

About the speaker

 
Alex Hodgson
Managing Director
1DegreeBio
Alex is the founder and CEO of 1DegreeBio, the first open-access, independent product review site for biological research products. Frustrated by the lack of digital tools for researchers, Alex and her team launched 1DegreeBio in the summer of 2010. Since its inception, 1DegreeBio has helped over 60,000 users connect with top quality antibodies and other reagents. As of 2011, 1DegreeBio was funded by Digital Science, an investment arm of MacMillian Publishers Ltd. Alex holds an Honors Bachelor's Degree from the University of Toronto, a Master of Business Administration (MBA) from Hult International Business School (formerly the Arthur D. Little School of Management), and an Organizational Change Management Certificate from Harvard University. Alex was named one of 50 Women to Watch in Tech by Femme-o-nomics in 2011.
 
 
Get More From MaRS   MaRS NEWSLETTERS
Facebook Twitter Vimeo Flickr

MaRS Charitable Registration Number
876682717 RR0001

Please enter your email address to subscribe to our newsletter